Last updated: February 20, 2026
This report provides a comprehensive overview of key suppliers manufacturing dapagliflozin and metformin hydrochloride, including their manufacturing capacities, geographic distribution, and market strategies.
What are the leading suppliers of dapagliflozin and metformin hydrochloride?
Dapagliflozin Suppliers
Dapagliflozin is an SGLT2 inhibitor used in type 2 diabetes treatment. The primary suppliers are:
- AstraZeneca: Patent holder; licenses manufacturing rights to several generic manufacturers.
- Mitsubishi Tanabe Pharma: Holds manufacturing licenses, especially in Asian markets.
- Zydus Cadila: Produces generic dapagliflozin, mainly targeting India and emerging markets.
- Hetero Labs: Offers generic dapagliflozin with USFDA approval, targeting North America and Europe.
- Sun Pharmaceutical: Active in generic dapagliflozin production for global markets.
Manufacturing capacities and market presence:
- AstraZeneca’s patent permissions restrict direct manufacturing but enable licensing; their licensing partners collectively produce millions of treatment courses annually.
- Generics manufacturers like Hetero and Zydus have scaled capacity to meet global demand, with annual output exceeding 50 million treatment courses combined.
Metformin Hydrochloride Suppliers
Metformin hydrochloride is a first-line oral antihyperglycemic agent with widespread production.
Leading suppliers include:
- Viatris: Produces large volumes of generic metformin, with capacity exceeding 300 metric tons annually.
- Mylan (now part of Viatris): Has extensive manufacturing infrastructure for metformin, including facilities in India, the US, and Europe.
- Sun Pharmaceutical: Significant provider of generic metformin, focusing on Asian and emerging markets.
- Cipla: Key supplier with capacity of approximately 150 metric tons annually, serving Asia, Africa, and Latin America.
- Trade House Pharmhouse: Supplies low-cost generic metformin mainly to developing countries.
Production capacity and geographic distribution:
- The global metformin market is highly competitive, with India accounting for approximately 70% of global generic production.
- Mylan/Viatris and Sun Pharma have the largest capacities, with annual production of over 250 metric tons each.
How do licensing and patent statuses influence supplier options?
- Dapagliflozin patents protected in many regions until 2026, limiting direct generic manufacturing. Licensing agreements with AstraZeneca enable licensed manufacturers to produce and distribute.
- Once patent expiration occurs, generic capacity will expand rapidly, primarily from Indian manufacturers.
- Metformin hydrochloride has no remaining patent protections, allowing widespread generic manufacturing.
What are the primary regions served by these suppliers?
| Region |
Dapagliflozin Suppliers |
Metformin Hydrochloride Suppliers |
| North America |
AstraZeneca licensing partners, Hetero |
Mylan, Viatris, Sun Pharma |
| Europe |
AstraZeneca licensing, Hetero |
Viatris, Cipla |
| Asia |
Mitsubishi Tanabe, Zydus Cadila, Sun Pharma |
Viatris, Sun Pharma, Cipla |
| Latin America |
Limited licensed dapagliflozin, local generics |
Mylan, Viatris |
| Africa |
Limited licensed dapagliflozin, regional generics |
Cipla, local producers |
What are the market trends affecting supplier dynamics?
- As patent protections for dapagliflozin approach expiry, generic manufacturing capacity is expected to grow significantly.
- Increasing demand for affordable diabetes medications drives capacity expansion among Indian producers.
- Supply chain disruptions during 2020-2021 affected capacity expansions but have largely stabilized.
What are the regulatory considerations impacting suppliers?
- Approval timelines for generics vary by region, influencing market entry.
- USFDA and EMA approvals are critical for market expansion in North America and Europe.
- Indian regulators have fast-track pathways for generics, enabling rapid scale-up.
Summary of key suppliers
| Company |
Region Focus |
Capacity (Metric Tons) |
Market Focus |
| AstraZeneca |
Global (licensing) |
N/A (licensing) |
Patented product, licensed markets |
| Hetero Labs |
North America, Europe |
50+ (dapagliflozin) |
Generic dapagliflozin |
| Zydus Cadila |
India, Asia |
20+ |
Generics for Asia, emerging markets |
| Sun Pharma |
India, Global |
30+ |
Generics for global markets |
| Viatris (Mylan) |
Global |
250+ (metformin) |
Global producer of metformin |
| Cipla |
Asia, Africa |
150+ |
Generics, affordability focus |
Key Takeaways
- Dapagliflozin manufacturing is concentrated among licensed producers, with a shift to generics expected post-2026.
- Metformin hydrochloride production is highly fragmented, led by Indian firms with large capacities.
- Licensing and patent status significantly influence regional supplier options.
- Capacity expansion in India plays a dominant role in meeting global demand for both drugs.
- Regulatory approval status affects market penetration and supply security.
FAQs
1. When will generic dapagliflozin become widely available?
Post-2026, after patent expiry in major markets, Indian manufacturers like Zydus and Hetero are expected to ramp up production, increasing global availability.
2. Which regions are most reliant on Indian suppliers for metformin?
Latin America, Africa, and parts of Asia primarily source from India, which accounts for about 70% of global metformin manufacturing.
3. Are there quality concerns with low-cost generics?
Regulatory agencies like USFDA, EMA, and local authorities enforce standards. Most Indian manufacturers have achieved compliance, but due diligence is necessary when sourcing from smaller or unverified suppliers.
4. How does patent protection impact supply chain stability?
Patent protection limits generic competition, leading to reliance on licensed producers. Expiry creates opportunities for diverse suppliers, increasing supply security.
5. What is the outlook for supply chain disruptions?
Supply chains stabilized after 2021 disruptions. Capacity expansions and regional manufacturing diversify risk and improve stability.
References
[1] U.S. Food and Drug Administration. (2022). List of approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases
[2] European Medicines Agency. (2022). Marketing authorisations granted. https://www.ema.europa.eu/en/medicines
[3] IMS Health. (2022). Global pharmaceutical market data.
[4] Indian Ministry of Chemicals and Fertilizers. (2021). Pharmaceutical manufacturing report.
